5,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione | 136529-54-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione
• 英文别名: 5,7-Dinitro-1,4-dihydro-chinoxalin-2,3-dion；5,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
• CAS: 136529-54-9
• 化学式: C₈H₄N₄O₆
• 分子量: 252.143
• InChiKey: YUVRBZPHIDJESL-UHFFFAOYSA-N

物化性质

• 密度：
  1.738±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  150
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,4,6-三硝基苯胺 在 硫化氢铵 、 乙酸甲酯 作用下， 生成 5,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione
  参考文献：
  名称：

  Horner et al., Justus Liebigs Annalen der Chemie, 1953, vol. 579, p. 212,220

  摘要：

  DOI：

文献信息

• A method for treating tension-type headache
  申请人：HEADEXPLORER ApS

  公开号：EP1829539A2

  公开（公告）日：2007-09-05

  Tension-type headache is treated by interacting with neuronal transmission in relation to pain in connection with headache in a way which prevents or decreases sensitization of second order nociceptive neurons. In particular, treatment is performed by administration of an effective amount of a substance which prevents or decreases central sensitization. Important examples of such substances are substances which interact with glutamate neurotransmission, such as glutamate receptor antagonists, such as NMDA receptor antagonists, such as MK-801 or Amitriptylline or Imipramine or Desipramine or Mirtazaprine or Venlafaxine. Other examples are substances which interact with nitric oxide, such as nitric oxide synthase (NOS) inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA. According to a broader aspect of the invention tension-type headache is treated by administration of substances which are effective in preventing or decreasing pain in connection with tension-type headache, such as the substances mentioned above. An additional aspect of the invention relates to treatment of tension-type headache by administration of substances which substantially inhibit the activity of nitric oxide synthase (NOS), such as NOS inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA.

  治疗紧张型头痛的方法是，与头痛有关的疼痛神经元传递相互作用，防止或减少二阶痛觉神经元的敏化。具体来说，治疗方法是通过施用有效量的物质来防止或减少中枢敏化。这类物质的重要例子是与谷氨酸神经递质相互作用的物质，如谷氨酸受体拮抗剂，如NMDA受体拮抗剂，如MK-801或阿米替林或丙咪嗪或地西普胺或米氮平或文拉法辛。其他例子包括与一氧化氮相互作用的物质，如一氧化氮合酶（NOS）抑制剂，如L-NMMA或L-NAME或L-NIO或L-NNA。根据本发明更广泛的一个方面，治疗紧张型头痛的方法是施用能有效预防或减轻紧张型头痛相关疼痛的物质，如上述物质。本发明的另一个方面涉及通过施用实质上抑制一氧化氮合酶（NOS）活性的物质，如NOS抑制剂，如L-NMMA或L-NAME或L-NIO或L-NNA，来治疗紧张型头痛。
• GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF
  申请人：The Regents of the University of California

  公开号：EP0647137B1

  公开（公告）日：2008-08-13
• Method for treating tension-type headache
  申请人：——

  公开号：US20040097562A1

  公开（公告）日：2004-05-20

  NMDA receptor antagonists, especially mirtazapine, can be used to treat tension-type headaches.
• COMBINATIONS OF NMDAR MODULATING COMPOUNDS
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20170072005A1

  公开（公告）日：2017-03-16

  This disclosure features combinations of NMDAR modulating compounds. This disclosure features combinations that include one or more NMDAR antagonists and GLYX-13 (each of which is sometimes referred to herein as a ‘component”). The beneficial effects of the combination are based, in part, on the finding that administration of GLYX-13 (e.g., a single dose) can reverse and/or prevent NMDAR antagonist-induced cognitive impairment (e.g., NMDAR antagonist-induced impairment in novel object recognition; e.g., induced through repeated dosing of the NMDAR antagonist).
• US5514680A
  申请人：——

  公开号：US5514680A

  公开（公告）日：1996-05-07